Abstract
The results of pivotal trials, which provide a rationale for marketing approval decisions for new drugs, are considered for various comparative purposes in postmarketing analyses. Using meta-regression analysis of 91 randomized controlled trials of 61 approved antihypertensive drugs in Japan, we show that mean baseline blood pressure (BP) of each arm was associated with predetermined entry criteria (EC), age, and trial start year (TSY). BP changes following treatment were associated with EC, subject characteristics (e.g., age, complications, baseline BP), study design (e.g., concomitant drug use), and TSY. Effect sizes were generally larger in trials for the first and second drugs in the same class than in trials for follow-on drugs. Results of pivotal trials may vary depending on many factors, suggesting possible challenges associated with the comparison of these results indirectly. Due to the heterogeneity in pivotal trials, caution should be exercised when comparing approved drugs and conducting meta-analyses retrospectively.
References
Jan 1, 1977·Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·T Ozawa, M Iwamoto
Mar 9, 1985·Lancet·J S GillP Davies
Dec 1, 1988·British Journal of Clinical Pharmacology·D J SumnerH L Elliott
Sep 1, 1983·Hypertension·F R Bühler
Apr 1, 1993·The New England Journal of Medicine·B J MatersonJ Gottdiener
Apr 1, 1996·The American Journal of Cardiology·R A KlonerM Wein
Mar 15, 1997·The American Journal of Cardiology·K A Spratt
Jul 1, 1997·Circulation·S S FranklinD Levy
Jul 19, 1997·BMJ : British Medical Journal·T PhilippS Wellek
Dec 29, 2000·Lancet·B NealUNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Aug 15, 2001·Circulation·R S KhattarA Lahiri
Oct 9, 2001·Lancet·UNKNOWN PROGRESS Collaborative Group
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Nov 15, 2003·Lancet·Fiona Turnbull, UNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Jan 25, 2006·The American Journal of Medicine·Russell V LuepkerHenry Blackburn
Sep 19, 2006·Journal of Clinical Epidemiology·A Rogier T DondersKarel G M Moons
Jul 8, 2008·International Journal of Technology Assessment in Health Care·Michael F DrummondSean D Sullivan
Dec 2, 2009·Nature Reviews. Drug Discovery·Bernard Munos
Mar 17, 2010·Lancet·Alastair J S WebbPeter M Rothwell
Dec 31, 2010·Clinical Pharmacology and Therapeutics·K I Kaitin, J A DiMasi
Feb 8, 2011·Lancet·Goodarz DanaeiUNKNOWN Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure)
Oct 1, 2011·Diabetes, Obesity & Metabolism·K EspositoD Giugliano
Apr 11, 2012·Diabetes, Obesity & Metabolism·S-C LiuK-L Chien
Apr 17, 2012·Lancet·Yoshiki Yui
Nov 15, 2012·BMJ : British Medical Journal·Benjamin D FoxAvi Shimony
Jun 1, 2013·Nature Reviews. Drug Discovery·Ulrik Schulze, Michael Ringel
Sep 23, 2014·Lancet·Yoshiki Yui
Jan 3, 2015·Systematic Reviews·David MoherUNKNOWN PRISMA-P Group
Feb 13, 2015·SpringerPlus·Satoshi FukunagaShunsuke Ono
Jul 30, 2016·Medicine·Marco A PazGabriel Coll-de-Tuero